Characteristics and outcomes of patients with anti-glomerular basement membrane antibody disease and anti-neutrophil cytoplasmic antibodies

Percy G. Balderia, Nicole Andeen, Jonathan A. Jefferson

Research output: Contribution to journalArticle

Abstract

Background: It is unclear whether patients with Anti-Glomerular Basement Membrane (GBM) disease and Anti-Neutrophil Cytoplasmic Antibodies (ANCA), so called “Double-Positive” (DP), have a different clinical presentation and outcome compared to patients with anti-GBM antibody disease alone. This study describes the clinical and histologic characteristics as well as the patient and renal outcomes of DP patients at the University of Washington compared to patients with anti-GBM antibody disease alone. Methods: Adults admitted to the University of Washington and Harborview Medical Centers from 2000 to 2016 who had a kidney biopsy showing anti-GBM disease characterized by crescentic glomerulonephritis with strong linear staining of glomerular basement membranes for IgG by im-munofluorescence were included. Subjects were classified into anti-GBM or DP based on serologic testing. Information on demographics, clinical presentation, biopsy findings, initial treatment, and rates of relapse and patient and renal survival were collected. Continuous and categorical variables were analyzed using the Mann-Whitney U and Fisher’s exact tests, respectively. Results: There were 6 anti-GBM and 7 DP patients. Two patients were lost to follow-up after one year. There was no significant difference in clinical presentation or outcomes between the two groups. Two DP patients had greater than 50% global glomerulosclerosis. All the subjects developed ESRD. Two DP patients had a relapse while off immunosuppression. Two patients in each group died within 5 years of diagnosis. Conclusion: Two DP patients in our cohort had a relapse within 5 years of diagnosis. Multicenter studies are needed to determine whether DP patients have a higher relapse rate and need prolonged immunosuppression.

Original languageEnglish (US)
Pages (from-to)224-228
Number of pages5
JournalCurrent Rheumatology Reviews
Volume15
Issue number3
DOIs
StatePublished - Jan 1 2019

Fingerprint

Antineutrophil Cytoplasmic Antibodies
Glomerular Basement Membrane
Anti-Glomerular Basement Membrane Disease
Recurrence
Kidney
Rapidly progressive glomerulonephritis with pulmonary hemorrhage
Immunosuppression
Biopsy
Lost to Follow-Up
Glomerulonephritis
Multicenter Studies
Chronic Kidney Failure

Keywords

  • Anti-glomerular basement membrane disease
  • Antineutrophil cytoplasmic antibodies
  • Glomerulonephritis
  • Immunosuppression
  • Initial treatment
  • Treatment outcome

ASJC Scopus subject areas

  • Rheumatology

Cite this

Characteristics and outcomes of patients with anti-glomerular basement membrane antibody disease and anti-neutrophil cytoplasmic antibodies. / Balderia, Percy G.; Andeen, Nicole; Jefferson, Jonathan A.

In: Current Rheumatology Reviews, Vol. 15, No. 3, 01.01.2019, p. 224-228.

Research output: Contribution to journalArticle

@article{81adda772525418e87d9d35068455287,
title = "Characteristics and outcomes of patients with anti-glomerular basement membrane antibody disease and anti-neutrophil cytoplasmic antibodies",
abstract = "Background: It is unclear whether patients with Anti-Glomerular Basement Membrane (GBM) disease and Anti-Neutrophil Cytoplasmic Antibodies (ANCA), so called “Double-Positive” (DP), have a different clinical presentation and outcome compared to patients with anti-GBM antibody disease alone. This study describes the clinical and histologic characteristics as well as the patient and renal outcomes of DP patients at the University of Washington compared to patients with anti-GBM antibody disease alone. Methods: Adults admitted to the University of Washington and Harborview Medical Centers from 2000 to 2016 who had a kidney biopsy showing anti-GBM disease characterized by crescentic glomerulonephritis with strong linear staining of glomerular basement membranes for IgG by im-munofluorescence were included. Subjects were classified into anti-GBM or DP based on serologic testing. Information on demographics, clinical presentation, biopsy findings, initial treatment, and rates of relapse and patient and renal survival were collected. Continuous and categorical variables were analyzed using the Mann-Whitney U and Fisher’s exact tests, respectively. Results: There were 6 anti-GBM and 7 DP patients. Two patients were lost to follow-up after one year. There was no significant difference in clinical presentation or outcomes between the two groups. Two DP patients had greater than 50{\%} global glomerulosclerosis. All the subjects developed ESRD. Two DP patients had a relapse while off immunosuppression. Two patients in each group died within 5 years of diagnosis. Conclusion: Two DP patients in our cohort had a relapse within 5 years of diagnosis. Multicenter studies are needed to determine whether DP patients have a higher relapse rate and need prolonged immunosuppression.",
keywords = "Anti-glomerular basement membrane disease, Antineutrophil cytoplasmic antibodies, Glomerulonephritis, Immunosuppression, Initial treatment, Treatment outcome",
author = "Balderia, {Percy G.} and Nicole Andeen and Jefferson, {Jonathan A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1573397114666180516131240",
language = "English (US)",
volume = "15",
pages = "224--228",
journal = "Current Rheumatology Reviews",
issn = "1573-3971",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Characteristics and outcomes of patients with anti-glomerular basement membrane antibody disease and anti-neutrophil cytoplasmic antibodies

AU - Balderia, Percy G.

AU - Andeen, Nicole

AU - Jefferson, Jonathan A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: It is unclear whether patients with Anti-Glomerular Basement Membrane (GBM) disease and Anti-Neutrophil Cytoplasmic Antibodies (ANCA), so called “Double-Positive” (DP), have a different clinical presentation and outcome compared to patients with anti-GBM antibody disease alone. This study describes the clinical and histologic characteristics as well as the patient and renal outcomes of DP patients at the University of Washington compared to patients with anti-GBM antibody disease alone. Methods: Adults admitted to the University of Washington and Harborview Medical Centers from 2000 to 2016 who had a kidney biopsy showing anti-GBM disease characterized by crescentic glomerulonephritis with strong linear staining of glomerular basement membranes for IgG by im-munofluorescence were included. Subjects were classified into anti-GBM or DP based on serologic testing. Information on demographics, clinical presentation, biopsy findings, initial treatment, and rates of relapse and patient and renal survival were collected. Continuous and categorical variables were analyzed using the Mann-Whitney U and Fisher’s exact tests, respectively. Results: There were 6 anti-GBM and 7 DP patients. Two patients were lost to follow-up after one year. There was no significant difference in clinical presentation or outcomes between the two groups. Two DP patients had greater than 50% global glomerulosclerosis. All the subjects developed ESRD. Two DP patients had a relapse while off immunosuppression. Two patients in each group died within 5 years of diagnosis. Conclusion: Two DP patients in our cohort had a relapse within 5 years of diagnosis. Multicenter studies are needed to determine whether DP patients have a higher relapse rate and need prolonged immunosuppression.

AB - Background: It is unclear whether patients with Anti-Glomerular Basement Membrane (GBM) disease and Anti-Neutrophil Cytoplasmic Antibodies (ANCA), so called “Double-Positive” (DP), have a different clinical presentation and outcome compared to patients with anti-GBM antibody disease alone. This study describes the clinical and histologic characteristics as well as the patient and renal outcomes of DP patients at the University of Washington compared to patients with anti-GBM antibody disease alone. Methods: Adults admitted to the University of Washington and Harborview Medical Centers from 2000 to 2016 who had a kidney biopsy showing anti-GBM disease characterized by crescentic glomerulonephritis with strong linear staining of glomerular basement membranes for IgG by im-munofluorescence were included. Subjects were classified into anti-GBM or DP based on serologic testing. Information on demographics, clinical presentation, biopsy findings, initial treatment, and rates of relapse and patient and renal survival were collected. Continuous and categorical variables were analyzed using the Mann-Whitney U and Fisher’s exact tests, respectively. Results: There were 6 anti-GBM and 7 DP patients. Two patients were lost to follow-up after one year. There was no significant difference in clinical presentation or outcomes between the two groups. Two DP patients had greater than 50% global glomerulosclerosis. All the subjects developed ESRD. Two DP patients had a relapse while off immunosuppression. Two patients in each group died within 5 years of diagnosis. Conclusion: Two DP patients in our cohort had a relapse within 5 years of diagnosis. Multicenter studies are needed to determine whether DP patients have a higher relapse rate and need prolonged immunosuppression.

KW - Anti-glomerular basement membrane disease

KW - Antineutrophil cytoplasmic antibodies

KW - Glomerulonephritis

KW - Immunosuppression

KW - Initial treatment

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85070518070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070518070&partnerID=8YFLogxK

U2 - 10.2174/1573397114666180516131240

DO - 10.2174/1573397114666180516131240

M3 - Article

VL - 15

SP - 224

EP - 228

JO - Current Rheumatology Reviews

JF - Current Rheumatology Reviews

SN - 1573-3971

IS - 3

ER -